| HOME >> BIOLOGY >> TECHNOLOGY |
dilutive shares consisting of 2,868,000 common stock equivalent
shares from the potential conversion of convertible debt securities
for the three months ended September 30, 2007 were not used in the
calculation of diluted net income per common share, or on an
adjusted cash basis, because inclusion thereof would be
antidilutive.
Inverness Medical Innovations, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and
Reconciliation to Non-GAAP Adjusted Cash Basis Amounts
(in $000s, except per share amounts)
Nine Months Ended September 30, 2008
Non-GAAP
Non-GAAP Adjusted Cash
GAAP Adjustments Basis(a)
Net revenue $1,212,160 $- $1,212,160
Cost of revenue 597,520 (53,560)(b)( c ) 543,960
(d)(e)
Gross profit 614,640 53,560 668,200
Gross margin 51% 55%
Operating expenses:
Research and development 86,426 (13,080)(b)( c )(d) 73,346
Purchase of in-process
research and development - -
Selling, general and
administrative 496,687 (142,286)(b)( c )(d) 354,401
Total operating expenses 583,113 (155,366) 427,747
Operating income
(loss) 31,527 208,926 240,453
Interest and other income
(expense), net (84,151) 8,615( c )(h) (7
'/>"/>
| SOURCE Inverness Medical Innovations, Inc. Copyright©2008 PR Newswire. All rights reserved |